Table 2.
Baseline patient characteristics by nerve-sparing status
| Bilateral | Unilateral | Non-nerve-sparing | p-value | |
|---|---|---|---|---|
| Number of patients | 159 | 32 | 62 | |
| Mean age (SD) | 59.4 (6.2) | 59.6 (6.8) | 65.6 (6.4) | <0.001† |
| BMI, kg/m2 (SD) | 26.7 (3.2) | 25.9 (3.3) | 27.6 (3.1) | 0.052† |
| Median follow-up, days | 601 | 579 | 541 | 0.690† |
| Mean prostate weight, g (SD) | 47.1 (19) | 46.1 (22) | 54.2 (21) | 0.051† |
| Gleason scores | <0.001†† | |||
| 5–6 | 57 | 3 | 9 | |
| 7 | 97 | 27 | 44 | |
| 8–10 | 3 | 2 | 8 | |
| Mean cancer volume, mL (SD) | 8.1 (9) | 8.3 (7) | 15.3 (13) | <0.001† |
| Capsular invasion | 32 | 8 | 32 | <0.001†† |
| Seminal vesicle invasion | 12 | 2 | 11 | 0.266†† |
| Bladder neck invasion | 0 | 1 | 3 | 0.077†† |
| Node positive disease | 0 | 1 | 2 | <0.001†† |
| Extra-prostatic extension | 32 | 11 | 31 | <0.001†† |
| Positive surgical margins | 15 | 6 | 18 | <0.001†† |
| Mean PSA level, ng/mL (SD) | 6.55 (6.4) | 6.24 (2.8) | 8.97 (6.5) | 0.029† |
| Mean blood loss, mL (SD) | 587 (408) | 616 (329) | 723 (552) | 0.131† |
| Mean baseline sexual function score (SD) | 1.7 (1.0) | 1.8 (1.0) | 2.4 (1.4) | 0.001† |
| Mean baseline urinary frequency score (SD) | 1.9 (0.8) | 1.8 (0.8) | 2.1 (0.8) | 0.150† |
| Mean baseline continence score (SD) | 1.3 (0.6) | 1.4 (0.6) | 1.5 (0.8) | 0.123† |
| Comorbidities | ||||
| 0 | 104 | 22 | 36 | 0.741 |
| 1 | 42 | 8 | 17 | |
| ≥2 | 13 | 2 | 8 | |
SD = standard deviation; BMI = body mass index; PSA = prostate-specific antigen;
†
= for ANOVA;
††
= for chi2 test.